PharMerica Corporation (NYSE:PMC), a national provider of institutional pharmacy and hospital pharmacy management services, announced that its Board of Directors, after careful consideration with its independent financial and outside legal advisors, voted unanimously to reject the unsolicited tender offer made by Omnicare (NYSE:OCR) to acquire PharMerica for $15.00 per share in cash. The Board determined that the offer undervalues PharMerica and is not in the best interests of PharMerica’s stockholders. In addition to undervaluing PharMerica and its future prospects, the Board believes the offer is illusory because it is subject to significant regulatory and other uncertainty. The Board unanimously recommends that PharMerica stockholders reject Omnicare’s offer and not tender their shares to Omnicare.

The Board noted that the value offered by Omnicare is unchanged from the unsolicited proposal it first made privately on July 19, 2011 and subsequently made public on August 23, 2011.

“The PharMerica Board of Directors is unanimous in its well-informed belief that Omnicare’s offer is lacking in both price and certainty of closing,” said Gregory S. Weishar, PharMerica Chief Executive Officer. “The PharMerica Board believes that the continued pursuit of our strategic plan will yield greater value for PharMerica stockholders than the Omnicare offer. Omnicare also remains stubbornly unwilling to provide any assurance to PharMerica stockholders that it will be in a position to complete a transaction in a timely manner at any price — and despite its professed confidence in attaining regulatory approval refuses to take on the contractual risk of closing. The PharMerica Board strongly urges stockholders to reject Omnicare’s deficient offer and not to tender their shares to Omnicare.”

PharMerica Corporation is a leading institutional pharmacy services company servicing healthcare facilities in the United States. PharMerica operates institutional pharmacies in 44 states. PharMerica’s customers are institutional healthcare providers, such as nursing centers, assisted living facilities, hospitals and other long-term care providers. The Company also provides pharmacy management services to long-term care hospitals.

More about PMC at www.pharmerica.com

*************************************

Good Times Restaurants Inc. (Nasdaq:GTIM) announced the return of its successful seasonal Sweet Potato Fries, which will be offered “Naked or Dusted” from now through the end of December.

Good Times Restaurants, Inc., through its subsidiary, Good Times Drive Thru Inc., engages in developing, owning, operating, and franchising hamburger-oriented drive-through restaurants under the Good Times Burgers & Frozen Custard name primarily in Colorado.

***********************************

Enzo Biochem Inc. (ENZ)

Enzo Biochem, Inc., is a growth-oriented integrated life sciences and biotechnology company focused on harnessing biological process to develop research tools, diagnostics and therapeutics, and serves as a provider of test services, including exotic tests, to the medical community. Since ENZ was founded in 1976, their strategic focus has been on the development of enabling technologies in the life sciences field.

The biotechnology industry is diverse. Biotechnology works in the field of creating new solutions to pressing health, environmental and economic challenges. Biotechnology applies scientific disciplines including chemistry, engineering, and physics and computing to living organisms to create innovative products and techniques. Genetic modification of plants and animals is used by agricultural biotechnology firms to combat the growing challenges presented by drought and malnutrition, and to decrease the environmental impact of agriculture.

Innovative household and industrial products and techniques developed by industrial and environmental biotechnology industry provide new solutions for environmental contamination and clean-up, water purification, and biodegradable detergents and solvents.

Enzo Biochem Inc. recently announced that it has added four highly experienced executives at its Enzo Life Sciences subsidiary to focus on rapidly evolving new pharmaceutical and clinical applications.

The officers, all filling newly created positions, are Bruce Taillon, PhD, as head of global technology business development, John D’Errico, PhD, to lead the commercial merchandising operations, Kara Cannon, as head of global marketing and Paul Munger, PhD, to lead Global Manufacturing.

Over the past two years, Enzo has been engaged in enhancing the Life Sciences subsidiary’s operating performance through added capabilities, greater integration and a more focused product mix. These efforts are all aimed at significantly expanding Enzo’s presence and marketing beyond the traditional academic and research laboratory core to greater penetrate the pharmaceutical and clinical customer base with new and cutting edge platform technologies.

For more information about Enzo Biochem Inc. visit its website: http://www.enzo.com

***********************************

Cleantech Transit, Inc. (CLNO)

Cleantech Transit Inc. was founded to capitalize on technology advances and manufacturing opportunities in the growing clean energy public transportation sector. The Company has expanded its focus to invest directly in specific green projects. Recognizing the many economic and operational advances of converting wood waste into renewable sources of energy, Cleantech has selected to invest in Phoenix Energy (www.phoenixenergy.net). This project could benefit the Company’s manufacturing clients worldwide.

Cleantech Transit, Inc. (CLNO) is pleased to announce it has met its funding requirement to secure the Company’s ability to earn in 25% of the 500KW Merced Project.

The Company is in the final stages of closing its initial interest in the Merced Project and is currently working on completing the necessary documentation and expects closing the transaction soon. As previously announced Cleantech has the option to earn up to 40% of the Merced Project and the Company plans to continue to work towards increasing its interest in the Merced Project as they move ahead.

Environmental benefits of biomass fuels are:

” Biomass fuels produce virtually no sulfur emissions, and help mitigate acid rain.
” Biomass fuels “recycle” atmospheric carbon, minimizing global warming impacts since zero “net” carbon dioxide is emitted during biomass combustion, i.e. the amount of carbon dioxide emitted is equal to the amount absorbed from the atmosphere during the biomass growth phase.
” The recycling of biomass wastes mitigates the need to create new landfills and extends the life of existing landfills.
” Biomass combustion produces less ash than coal, and reduces ash disposal costs and landfill space requirements. The biomass ash can also is used as a soil amendment in farm land.
” Energy crops (grasses and trees) have distinctly lower environmental impacts than conventional farm crops. Energy crops require less fertilization and herbicides and provide greater vegetative cover throughout the year, providing protection against soil erosion and watershed quality deterioration, as well as improved wildlife cover.
” Landfill gas-to-energy projects turn methane emissions from landfills into useful energy.

For more information about Cleantech Transit, Inc. visit its website www.cleantechtransitinc.com

***********************************

Capstone Turbine Corp. (Nasdaq:CPST) announced that microturbines are now eligible for California’s Self Generation Incentive Program (SGIP), an incentive program designed to promote the deployment of distributed generation technologies that reduce greenhouse gases.

Capstone Turbine Corporation develops, manufactures, markets, and services turbine generator sets and related parts for use in stationary distributed power generation applications.

**************************************************************

**************************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company.Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.Crown Equity Holdings Inc. (CRWE.OB) has received 1,000,000 shares of 144 restricted stocks from the company for 12 months of media advertisement and IR services and 4,000,000 shares of 144 restricted stocks from the company for management fee through end of June for Cleantech Transit, Inc. (CLNO.OB).

(more…)

Offer Undervalues PharMerica and Provides No Certainty of Closing

LOUISVILLE, Ky.–(CRWENewswire)– PharMerica Corporation (NYSE:PMC), a national provider of institutional pharmacy and hospital pharmacy management services, today announced that its Board of Directors, after careful consideration with its independent financial and outside legal advisors, voted unanimously to reject the unsolicited tender offer made by Omnicare (NYSE:OCR) to acquire PharMerica for $15.00 per share in cash. The Board determined that the offer undervalues PharMerica and is not in the best interests of PharMerica’s stockholders. In addition to undervaluing PharMerica and its future prospects, the Board believes the offer is illusory because it is subject to significant regulatory and other uncertainty. The Board unanimously recommends that PharMerica stockholders reject Omnicare’s offer and not tender their shares to Omnicare.

The Board noted that the value offered by Omnicare is unchanged from the unsolicited proposal it first made privately on July 19, 2011 and subsequently made public on August 23, 2011.

“The PharMerica Board of Directors is unanimous in its well-informed belief that Omnicare’s offer is lacking in both price and certainty of closing,” said Gregory S. Weishar, PharMerica Chief Executive Officer. “The PharMerica Board believes that the continued pursuit of our strategic plan will yield greater value for PharMerica stockholders than the Omnicare offer. Omnicare also remains stubbornly unwilling to provide any assurance to PharMerica stockholders that it will be in a position to complete a transaction in a timely manner at any price — and despite its professed confidence in attaining regulatory approval refuses to take on the contractual risk of closing. The PharMerica Board strongly urges stockholders to reject Omnicare’s deficient offer and not to tender their shares to Omnicare.”

The Board’s reasons for rejecting Omnicare’s unsolicited offer include its beliefs that:

* Omnicare’s unsolicited offer undervalues PharMerica and its future prospects.

- The Board has confidence in PharMerica’s strategic plan, which is focused on client retention, customer service, and improving its core pharmacy services and acquisitions, and believes that execution of the plan will deliver greater value to its stockholders than would be obtained under the current Omnicare offer.

- PharMerica recently completed acquisitions of Ark Pharmacy and ChemRx, and is just beginning to realize the significant value creation potential of these acquisitions.

- Omnicare’s offer fails to appropriately compensate PharMerica stockholders for the synergies Omnicare would derive from combining the largest and second largest players in the institutional pharmacy market.

- PharMerica is the second largest institutional pharmacy services company in the United States based on revenues and is the largest remaining independent public company in the institutional pharmacy market. Omnicare’s offer does not reflect the unique strategic value of PharMerica to Omnicare.

* The offer is illusory because it is subject to significant regulatory and other uncertainty.

- A transaction with Omnicare would likely undergo a lengthy regulatory review process with no assurance of Omnicare’s ability to complete a transaction on a timely basis or at all. Antitrust clearance to combine competitors with #1 and #2 market share in institutional pharmacy is likely to be difficult to achieve and involve lengthy administrative and court proceedings.

- Even if the antitrust issues could eventually be resolved in a satisfactory manner, the offer introduces unacceptably high risk to PharMerica stockholders and would have a material adverse effect on PharMerica’s ability to attract and retain key personnel, employees and customers.

- In light of recent actions by the Department of Justice, including its decision to sue to stop AT&T’s proposed acquisition of T-Mobile USA, the PharMerica Board believes the current environment is not conducive to obtaining timely regulatory approval for a combination with Omnicare.

- While Omnicare has publicly expressed its confidence in a timely regulatory approval, it has been unwilling to take on the contractual risk of closing.

- Given the regulatory uncertainty and the significant conditionality of Omnicare’s offer, there is considerable uncertainty regarding the offer and the timing of PharMerica stockholders receiving the $15.00 that Omnicare claims to be offering.

- Because Omnicare is a competitor of PharMerica, there are also serious competitive risks to PharMerica and its business in providing non-public information to Omnicare if the transaction is not completed due to antitrust, regulatory, or other issues.

* The timing of Omnicare’s unsolicited offer is opportunistic and disadvantageous to PharMerica’s stockholders.

- The offer is being made at a time when Omnicare can take advantage of PharMerica’s lower stock valuation resulting from regulatory uncertainty in the healthcare industry due to new healthcare legislation.

- The offer is being made in advance of the wave of branded to generic drug conversions that will happen in 2012 and beyond, which is expected to be beneficial to PharMerica’s operating results.

- After its unsolicited proposal was rejected privately in July as being inadequate, Omnicare publicized it during a period of market volatility in order to claim an inflated premium.

The full basis for the Board’s recommendation is set forth in PharMerica’s Schedule 14D-9 filed today with the Securities and Exchange Commissions.

Deutsche Bank Securities Inc. is acting as financial advisor and Holland & Knight LLP is acting as legal advisor to PharMerica.

About PharMerica

PharMerica Corporation is a leading institutional pharmacy services company servicing healthcare facilities in the United States. PharMerica operates institutional pharmacies in 44 states. PharMerica’s customers are institutional healthcare providers, such as nursing centers, assisted living facilities, hospitals and other long-term care providers. The Company also provides pharmacy management services to long-term care hospitals.

Additional Information

This communication does not constitute an offer to buy or solicitation of an offer to sell any securities. In response to the tender offer, PharMerica will file a solicitation/recommendation statement on Schedule 14D-9 with the U.S. Securities and Exchange Commission (“SEC”). INVESTORS AND STOCKHOLDERS OF PHARMERICA ARE URGED TO READ THESE AND OTHER DOCUMENTS FILED WITH THE SEC CAREFULLY IN THEIR ENTIRETY BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION. Investors and stockholders may obtain free copies of these documents and other documents filed with the SEC by PharMerica through the web site maintained by the SEC at http://www.sec.gov. In addition, documents filed with the SEC by PharMerica may be obtained free of charge by contacting PharMerica’s information agent, Georgeson Inc., at (866) 647-8872.

Forward Looking Statements

This press release contains “forward-looking statements,” including, but not limited to, statements regarding PharMerica’s strategic plan, prospects, value of the Omnicare offer, regulatory uncertainty, and impact of the conversion of branded to generic drug conversions. These forward-looking statements are based upon information currently available to us and are subject to a number of risks, uncertainties and other factors that could cause the Company’s actual results, performance, prospects or opportunities to differ materially from those expressed in, or implied by, these forward-looking statements. These factors and risks include, but are not limited to, the outcome of, or developments concerning, the Offer; other potential commercial or business combination proposals that have or may be received in the future; the outcome of any litigation related to the Offer or any other offer or proposal and the Board’s recommendation to the stockholders concerning the Offer or any other offer or proposal; PharMerica’s access to capital, credit ratings, indebtedness, and ability to raise additional financings and operate under the terms of PharMerica’s debt obligations; the effects of adverse economic trends or intense competition in the markets in which PharMerica operates; the effects of retaining existing customers and service contracts and PharMerica’s ability to attract new customers for growth of PharMerica’s business; PharMerica’s ability to successfully pursue PharMerica’s development and acquisition activities and successfully integrate new operations and systems, including the realization of anticipated revenues, economies of scale, cost savings, and productivity gains associated with such operations; PharMerica’s ability to control costs, particularly labor and employee benefit costs, rising pharmaceutical costs, and regulatory compliance costs; the effects of healthcare reform and government regulations, including, interpretation of regulations and changes in the nature and enforcement of regulations governing the healthcare and institutional pharmacy services industries; changes in the reimbursement rates or methods of payment from Medicare and Medicaid and other third party payers to both PharMerica and its customers; PharMerica’s ability to anticipate a shift in demand for generic drug equivalents and the impact on the financial results including the negative impact on brand drug rebates; and other factors, risks and uncertainties referenced in PharMerica’s filings with the SEC, including the “Risk Factors” set forth in PharMerica’s Annual Report on Form 10-K for the year ended December 31, 2010. You are cautioned not to place undue reliance on any forward-looking statements, all of which speak only as of the date of this press release. Except as required by law, we undertake no obligation to publicly update or release any revisions to these forward-looking statements to reflect any events or circumstances after the date of this press release or to reflect the occurrence of unanticipated events. All written and oral forward-looking statements attributable to us or any person acting on the Company’s behalf are expressly qualified in their entirety by the cautionary statements contained or referred to in this press release and in the Risk Factors section set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC and in other reports filed with the SEC by the Company.

Contact:

PharMerica Corporation
Michael J. Culotta, 502-627-7475
Executive Vice President and Chief Financial Officer
or
Sard Verbinnen & Co
David Reno/Meghan Stafford, 212-687-8080

Source: PharMerica Corporation

*********************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. crwenewswire.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer (Read more at http://www.crwenewswire.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold crwenewswire.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.

Alexco Resource Corporation (AMEX:AXU) announced dramatically improved revenue, gross profit, earnings and production for its fiscal year ended June 30, 2011,Net income for year of $3.5 million ($0.06 basic and diluted earnings per share) and pre-tax income of $4.1 million on combined mining and environmental services revenue of $45.1 million. Cash flows from operating activities of $10.7 million. Bellekeno mine revenue of $38.3 million and gross profit of $15.8 million over its first six months of commercial production, on sales of 7,956 tonnes of lead-silver and zinc concentrate. Production of 911,848 ounces silver, 7,756,426 pounds lead and 3,104,303 pounds zinc

Alexco Resource Corp. engages in the exploration and development of mineral properties in Canada, primarily in Yukon Territory.

*****************************************

MAJESTIC GOLD CORP (MJGCF.PK)

The combination of gold’s relative scarcity and its obvious beauty has made it a very valuable commodity throughout the history of humanity. The physical and chemical properties of gold make it ideal for a number of applications. It is very stable (does not corrode or rust) and as a result seldom combines with other elements. It conducts heat and electricity very well (only silver is a better conductor of electricity). Its malleability and ductility have made it a favorite for jewelry making throughout the centuries.

MAJESTIC GOLD CORP (MJGCF.PK) engages in the exploration and development of mineral properties in China. The company focuses on its gold project located in the prolific gold region of Song Jiagou in eastern Shandong Province. Majestic Gold Corp. is headquartered in Vancouver, Canada.

MAJESTIC GOLD CORP (MJGCF.PK) has arranged a $10,000,000 loan to advance its Song Jiagou project in China. Nine million dollars ($9,000,000) from the proceeds from the loan will be used by the Company to in connection with its Song Jiagou project and the balance of one million dollars ($1,000,000) for general working capital purposes.

The loan will have a one year term and loan principal will be convertible at the option of the lender in whole or in part into common shares (”Shares”) of the Company until twelve months from the date of the loan advance at the price of $0.205 per Share. The loan will bear interest at the rate of 7.5% per annum, payable on maturity, and accrued and unpaid interest will be convertible at the option of the lender in whole or in part into shares of the Company until twelve months from the date of the loan advance at Market Price at the time of conversion.

The lender is at arm’s length from the Company and will not become an insider as a result of any conversion of principal and interest. All shares issued on any conversion of loan principal or interest will be subject to a four month hold period from the date of advance of loan proceeds. The loan is subject to acceptance by the TSX Venture Exchange.

As additional consideration for the loan, the Company has agreed to forward at least $9 million to Majestic Yantai Gold Ltd., a British Virgin Islands company owned 94% by the Company to be used to further advance its Song Jiagou project. The Borrower has also agreed to a 90 day period for reciprocal due diligence reviews and discussions for the possible further involvement of the Lender in the Song Jiagou project.

In the event that no further agreement is reached between the Lender and the Company during the 90 day period, then the loan and a minimum of seven (7) months interest will automatically convert to shares in the Company at a price of $0.205 per share and the interest at Market Price respectively. In addition the Company is pleased to announce that it has arranged a non-brokered private placement of up to 15,000,000 shares to be issued at the price of $0.20 per share for gross proceeds of $3,000,000.

For more information about MAJESTIC GOLD CORP. visit its website: http://www.majesticgold.net

*****************************************

PMC Commercial Trust (AMEX:PCC) announced that its Board of Trust Managers has declared a third quarter 2011 quarterly cash dividend of $0.16 per common share payable on October 11, 2011 to shareholders of record on September 30, 2011. The dividend is our 71st consecutive quarterly dividend.

PMC Commercial Trust operates as a real estate investment trust (REIT). It primarily originates loans to small businesses, principally in the limited service hospitality industry, collateralized by first liens on the real estate of the related business.

*****************************************

Evolution Petroleum Corp. (AMEX:EPM) declared a monthly cash dividend on its perpetual non-convertible 8.5% Series A Cumulative Preferred Stock. The dividend is for the month of September 2011, and is payable on September 30, 2011 to holders of record at the close of business on September 19, 2011. The payment will be 1/12th of the 8.5% annualized amount, or approximately $0.177083 per share, based on the $25.00 per share liquidation preference.

Evolution Petroleum Corporation, together with its subsidiaries, engages in the acquisition, exploitation, and development of properties for the production of crude oil and natural gas in the United States.

**************************************************************

**************************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company.Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.

Proper Power & Energy, Inc. (PPWE)
Oil and natural gas are great energy sources, since they pack a lot of energy into a small space. Energy is released when the carbon-hydrogen molecules oxidize (burn) creating CO2 and H2O. Oil and natural gas are a type of chemical energy. The energy comes from the fact that oil and natural gas are not in their most stable form on the surface of the earth.

Oil and natural gas are a non-renewable energy source. There are many uses for oil and natural gas. Oil is made into the fuels we use for transportation, as well as products such as plastic and asphalt for roads. Natural gas is used for heating, cooking, fertilizer, electric power generation, and to make hydrogen. Natural gas is a great source of hydrogen fuel, as it has four hydrogen atoms for every carbon atom.

Proper Power & Energy, Inc. is an independent exploration and production company. The Company’s operations are in Kentucky, which provides for low risk developmental drilling and production, and Utah, where the Company controls over 11,000 acres for its exploratory prospect. Renowned geophysicist and consultant to Proper Power, Robert Dunbar, believes the Utah prospect could hold up to one billion barrels of recoverable oil.

Proper Power & Energy, Inc. recently released a letter to shareholders from the company’s President, Andrew J. Kacic.

The Company continues to timely file its quarterly and annual reports with the SEC. Proper Power & Energy looks forward to having a very productive 2011, and anticipates announcing the first revenues from the sale of oil this quarter. Additionally, the Company plans to drill additional wells on its Kentucky property no later than the first month of the second quarter of 2011. The Company also intends to commence exploratory drilling to prove out the reserves on its Utah property potentially by third quarter of this year. According to the company, the current price of oil, combined with the rising demand for domestic production makes this year a very promising one for them.

For more information about Proper Power & Energy visit its website www.proerpower.com

*******************************************************************************

Lattice Semiconductor Corporation (Nasdaq:LSCC) announced a portfolio of Compression and Encryption IP cores, available now, for the LatticeECP3™ FPGA family. The portfolio features a Payload Compression System core that enables improved utilization of constrained channel bandwidth, making it ideal for use in Microwave Backhaul applications, Broadband Wireless Access for 802.16e (WiMAX), and, potentially, other Multi-Link Multi-In Multi-Out (MIMO) applications. The IP core is seamlessly scalable from 500Mbps to over 3Gbps in the LatticeECP3 device, and may be used in typical networking applications at either Layer 2 or Layer 3. The IP core uses a very robust and mature implementation of the LZRW lossless compression algorithm, which has been in production use by Helion customers for more than five years.

Lattice Semiconductor Corporation designs, develops, and markets programmable logic products and related software.

*****************************************

PMC-Sierra Inc. (Nasdaq:PMCS) will present a live webinar on OTN and the emergence of the P-OTP on Wednesday, March 30, 2011 at 9:00 AM PT. The webinar discusses how transport networks worldwide are steadily evolving from a pure SONET/SDH-centric infrastructure to one that better supports packet traffic. Register now for this free webinar at http://www.pmc-sierra.com/webinars/potn.html.

PMC-Sierra, Inc. engages in the design, development, marketing, and support of semiconductor solutions for the enterprise infrastructure and communications infrastructure markets.

*****************************************

UniTek Global Services, Inc. (Nasdaq:UNTK) announced that it will report financial results for the fourth quarter and year end on Wednesday, March 30, 2011 after the close of trading. The Company will host a conference call to discuss the results on Thursday, March 31, 2011 at 8:30 a.m. Eastern time. Interested parties may access the conference call by dialing 1-877-674-6428 in the United States, or 1-708-290-1372 if calling internationally, approximately five minutes prior to the start of the call and requesting conference call 51387943.

UniTek Global Services, Inc. provides engineering, construction management, and installation fulfillment services to companies specializing in the telecommunications, broadband cable, and satellite industries in the United States and Canada.

**************************************************************

**************************************************************************

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.Crown Equity Holdings Inc. (CRWE.OB) received 1,000,000 shares of free trading shares from a third party (Mohamad Nehmeh) for two (2) weeks of advertisement services for Proper Power & Energy, Inc. (PPWE.OB).

________

Proteonomix, Inc. (PROT) Plans European Investor Road Show

-Michael Cohen, Chairman and CEO, to Visit Several European Cities to Discuss Company’s Growth Plan and Future Outlook With Investors

PROTEONOMIX, INC. (OTC.BB:PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, announced last week that Mr. Michael Cohen, Chairman and CEO, is scheduling a multi-city European road trip to create additional awareness of the Proteonomix, Inc. investment opportunity to institutional investors.

Scheduled for early October, Mr. Cohen will discuss with sophisticated investors the recent contract to establish a joint venture with a group of investors that will establish a new stem cell treatment and research facility in the United Arab Emirates (U.A.E.). In addition, Mr. Cohen will discuss the opportunity to set up additional joint ventures in other countries using the U.A.E. arrangement as a model.

The recent contract calls for the joint venture partner to invest $5 million on or before September 10, 2010 in a Joint Venture company, XGEN Medical LLC. (”XGen”), a Nevis Island limited liability company.

For additional details about the joint venture agreement, please refer to the August 17, 2010 press release.

“Proteonomix has made great strides recently,” stated Mr. Cohen, “and we have been contacted by several European entities that have requested additional information about our proprietary stem cell activities. In recognition of the interest in Europe and the potential for additional joint venture agreements in various European countries, we recognize that it is propitious to meet with a number of the European institutional investors both to educate them on the intrinsic value of Proteonomix shares and garner interest in strategic relationships.”

Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteoderm, Inc. is a wholly owned subsidiary of Proteonomix that has recently opened its retail web site, Proteoderm.com, and begun accepting pre-orders for its anti-aging line of skin care products. StromaCel, Inc.’s goal is the development therapeutic modalities for the treatment of Cardiovascular Disease (CVD).

http://www.proteonomix.com/

________

Computer Programs and Systems, Inc. (NASDAQ:CPSI)

CPSI, a leading provider of healthcare information solutions, recently announced results for the second quarter and six months ended June 30, 2010.

The Company also announced that its Board of Directors has declared a regular quarterly cash dividend of $0.36 (thirty-six cents) per share, payable on August 27, 2010, to stockholders of record as of the close of business on August 12, 2010.

Total revenues for the second quarter ended June 30, 2010, increased 22.3% to $37.7 million, compared with total revenues of $30.8 million for the prior-year period. Net income for the quarter ended June 30, 2010, increased 20.4% to $4.3 million, or $0.39 per diluted share, compared with $3.5 million, or $0.32 per diluted share, for the quarter ended June 30, 2009. Cash provided by operations for the second quarter of 2010 was $2.8 million, compared with $3.7 million of cash provided by operations for the prior-year period.

http://www.cpsinet.com

________

PharMerica Corporation Announces Share Repurchase Program

PharMerica Corporation (NYSE: PMC), a national provider of institutional pharmacy and hospital pharmacy management services, recently announced that its Board of Directors has authorized the repurchase of up to $25 million of the Company’s common stock. The share repurchases will be made in the open market through unsolicited or solicited privately negotiated transactions, or in such other appropriate manner, and will be funded from available cash.

The amount and timing of the repurchases will be determined by the Company’s management and will depend on a variety of factors including price, corporate and regulatory requirements, capital availability and other market conditions. Common stock acquired through the share repurchase program will be held as treasury shares and may be used for general corporate purposes, including reissuances in connection with acquisitions, employee stock option exercises or other employee stock plans.

The share repurchase program does not have an expiration date and may be limited, terminated or extended at any time without prior notice.

PharMerica Corporation is a leading institutional pharmacy services company servicing healthcare facilities in the United States. As of June 30, 2010, PharMerica operated 90 institutional pharmacies in 41 states. PharMerica’s customers are institutional healthcare providers, such as nursing centers, assisted living facilities, hospitals and other long-term care providers. The Company also provides pharmacy management services to long-term care hospitals.

www.pharmerica.com

________

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!

Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. DrStockPick.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold DrStockPick.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (Read more at http://drstockpick.com/disclaimer) .Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings, Inc. (CRWE.OB) has received twenty thousand dollars in cash and twenty thousand dollars in free trading shares from a third party (Swiss Financial Report) for (30) days of advertisement services for Proteonomix, Inc. (PROT.OB).